期刊名称：CLINICA CHIMICA ACTA
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Clinica Chimica Acta publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids, cells or tissues The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are considered in they are clearly and directly relevant to human disease. Development and evaluation of novel analytical methologies where applicable to clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered.
In addition to original Research Communications the journal publishes: (1) Short Communications-concise reports of limited scope which offer conclusive results or document methodological advances; (2) Letters to the Editor, commenting on papers published in Clinica Chimica Acta - these should be less than 400 words and may include 1 illustration or 1 table; (3) Invited Critical Reviews of recent central developments in medical biochemistry and laboratory medicine; (4) case reports involving interesting or novel clinical laboratory data; (5) Newsletters of Scientific Societies; (6) Meeting announcements.
Typescripts submitted to Clinica Chimica Acta should not have been published previously and should not be under consideration for publication elsewhere. The agreement of all named authors to the submission must be affirmed. Relevant ethical approval must be noted for investigations involving human or animal subjects. Authors are invited to consult any member of the Editorial Board, if in doubt about any aspect of scope, format or content of a proposed paper.
Instructions to Authors
CCA - AIMS & SCOPE
Clinica Chimica Acta publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids, cells or tissues. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are considered when they are clearly and directly relevant to human disease. Development and evaluation of novel analytical methologies where applicable to clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered.
PUBLICATIONS
Original Research Communications: Peer-reviewed, high-quality, concise research investigations that represent new and significant contributions to science.
Letters to the Editor: commenting on papers published in Clinica Chimica Acta - these should be less than 400 words and may include 1 illustration or 1 table.
Invited Critical Reviews of recent central developments in medical biochemistry and laboratory medicine.
Case reports involving interesting or novel clinical laboratory data.
Meeting announcements.
Consensus recommendations or guidelines on the use of laboratory test for clinical practice will be considered if they are compiled by a recognized organization or expert panel (e.g. IFCC, IUPAC, AACC, etc). Please contact the appropriate Editor-in-Chief for consideration. The responsibility for such material remains with the originating body.
Manuscript submission
A manuscript is accepted for consideration for publication in Clinica Chimica Acta with the understanding that it has not been published previously (except in abstract form or as part of a public lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication has been approved by all the authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out and that, if accepted, it will not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors-in-Chief and the Publisher. Reference should be made to previously published abstracts, etc. in the introductory section. Responsibility for the accuracy of the material in the manuscript, including bibliographic citations, lies entirely with the authors. Relevant ethical approval must be noted for investigations involving human or animal subjects. Authors are invited to consult any member of the Editorial Board, if in doubt about any aspect of scope, format or content of a proposed paper.
A submission letter should always accompany the submitted paper, providing the following information:
(a) The full name and address of the corresponding author (including telephone and fax numbers and E-mail address).
(b) Any known changes of address within a period of six months after submission of the paper.
(c) The type of paper (Original Research communication, Short communication, Letter to the Editor, Critical Review etc).
(d) The full title of the submitted paper.
(e) The names, addresses and telephone, fax and e-mail details (where possible) of three suitable, potential reviewers.
If there are compelling reasons for excluding some individuals as potential reviewers, these may be mentioned. However, the ultimate reviewer selection is at the Editors-in-Chief's discretion.
One original and three copies are required of all material submitted, including the submission letter. All figures should be provided in quadruplicate and all four sets of figures should be labelled. Copies of relevant papers that are submitted elsewhere or 'in press', should be provided.
Manuscripts intended for publication in CCA should be sent to one of the Editors-in-Chief at the following locations:
For the Americas, Japan and Asia:
Dr. A.H. Wu
Department of Pathology and Laboratory Medicine
Hartford Hospital
80 Seymour Street
Hartford, CT 06102-5037
USA
Tel: +1 (860) 545 5221
Fax: +1 (860) 217 0361
E-mail: us-cca@comcast.net
For Europe, Australia and all other territories:
Professor D.W. Moss
Department of Metabolic Medicine
Imperial College School of Medicine
Hammersmith Hospital
London,W12 0NN
UK
Fax: +44 20 8383 3232
E-mail: uk_cca@btinternet.com
Reviews from all areas:
Dr. G.S. Makowski
Department of Laboratory Medicine
MC-2235
University of Connecticut Health Center
263 Farmington Avenue
Farmington, CT 06030-2235
USA
Fax: +1 (860) 679 2596
E-mail: Makowski@nso1.uchc.edu
The Editors-in-Chief are responsible for the professional review of the manuscripts. Receipt of manuscripts by the Editors-in-Chief will be acknowledged.
All materials submitted becomes the property of CCA. In the case of rejection of a paper, manuscripts will not be returned to authors. Authors should therefore stipulate whether half-tone illustrations should be returned.
Ethics
When conducting scientific research using human tissue and which is intended for publication in CCA, authors should follow procedures that are in accordance with the ethical standards as formulated in the Helsinki Declaration of 1975 (revised 1983). When conducting experiments on animals, authors should adhere to the local or national requirements for the care and use of laboratory animals.
Revision and publication dates
Manuscripts requiring revision and/or condensation will be returned to the authors by the Editors-in-Chief, specifying the requested alterations and including the (anonymous) referee reports. Authors are requested to resubmit the revised manuscript within three months. Papers not resubmitted within three months will be treated as new submissions.
Proofreading
Authors of Original Research Communications, Short Communications, Review articles and Case Reports will receive proofs. As acceptance is based upon the submitted version of the paper, it is essential that no new material be inserted in the text at the time of proofreading; furthermore, no alterations to style or meaning will be permitted at this stage. Any new material that the authors may wish to introduce, for reasons of scientific accuracy, will be checked by the Editors-in-Chief and a charge may be made for corrections. Authors are encouraged to return their proofs by fax. Elsevier will do everything possible to get your article corrected and published as quickly and accurate as possible. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication. Subsequent corrections will not be possible, so please ensure your firste sending is complete.
Page charges: There are no page charges
Offprints
Twenty five free offprints are provided free of charge to the corresponding author of each article. An offprint order form, price list and copyright transfer form are sent upon receipt of the manuscript at the Publisher so that extra offprints may be ordered if required. It is essential that copyright be transferred at this stage.
Publication
For enquiries relating to the submission of articles (including electronic submission where available) please visit the Author Gateway from Elsevier Science at http://authors.elsevier.com. The Author Gateway also provides the facility to track accepted articles and set up e-mail alerts to inform you of when an article's status has changed, as well as detailed artwork guidelines, copyright information, frequently asked questions and more.
Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided when an article is accepted for publication by Elsevier.
Authors in Japan please note:
Upon request, Elsevier Science Japan will provide authors with a list of people who can check and improve the English of their paper (before submission). Please contact our Tokyo office: Elsevier Science K.K., 9-15 Higashi-Azabu,1-chome,Minato-ku, Tokyo 106-0044, Japan; Tel. +81 3-5561-5033; Fax: +81 3-5561-5047, E-mail: info@elsevier.co.jp
PREPARATION OF PAPERS
Authors should consult a recent issue of the journal to make themselves familiar with the conventions and layout of articles.
Full length papers should be submitted in quadruplicate. The entire text, including figure and table legends and the reference list, should be typed (or printed out) on one side of standard A4 or 8.5" X 11" white bonded paper with double spacing, leaving a left margin of approx. 3 cm (1"). All pages should be numbered consecutively, starting with the title page of the manuscript. Every new paragraph should be clearly indented. Handwritten characters should be clearly defined in the margins. Expressions of Latin origin, for example, in vivo, in vitro, et al., per se, should be typed in normal typeface. They should be neither italicized nor underlined. Do not use right-hand justification as it alters word spacings.
Title page. Page 1 should be concise, descriptive and informative. It should include:
(1) The title of the article;
(2) The authors' full names (first name, middle initial(s),and surname); (3) Affiliations (the name of department (if any), institution, city and state or country where the work was done), indicating which authors are associated with which affiliation;
(4) Acknowledgement of grant support and of individuals who were of direct help in the preparation of the study;
(5) Disclaimers, (if any);
(6) The name, address, telephone and fax numbers and E-mail address of the corresponding author and, if different, the author to whom the 50 free offprints are to be sent.
Authors are requested to select a maximum of six key words and to present them on the title page of the typescript. These key words will be used in the compilation of the annual cumulative index. They should cover precisely the contents of the submitted paper and should give readers sufficient information as to the relevance of the paper to his/her particular field.
Abstract. Page 2 of the typescript should be reserved for the Abstract which should have no more than 200 words. This should follow a structured format, sub-divided into subsections entitled "Background"; "Methods"; "Results"; and "Conclusions". Each subsection should be brief and informative, emphasizing those points that are unique to the paper. Since summaries are increasingly used by abstracting services which will cut off after a fixed number of words, it is important not to exceed the maximum number of words and to avoid bibliographic references and non-standard abbreviations.
Text. After the Abstract, Original Research Communications should be organized in the following format: Introduction, Materials and methods, Results, Discussion, Acknowledgements, List of abbreviations, References.
Introduction
This is a short section in which the authors should clearly state the reasons for and aims of the investigation.Summarise the rationale for the study and hypothesis tested by it, with brief reference to relevant previous work.
Materials and methods
The section Materials and methods should be detailed enough for readers to reproduce the experiments. Authors should always refer to other work on the same subject, indicating whether or not their experimental results are in agreement with previous work. Conclusions drawn from experiments described in the tables or figures can often appear most conveniently in the Results section.
Result and Discussion
The overall conclusions based on the work reported should be given in the Discussion. In some cases, Results and Discussion sections may more appropriately be combined than separated (at the author's discretion). Every effort should be made to avoid jargon, to spell out all non-standard abbreviations the first time they are mentioned and to present the contents of the study as clearly and concisely as possible.
Short Communications
These are of two types:
(1) complete reports of limited scope offering conclusive results;
(2) brief reports of new or improved methods.
The former should be less than 1500 words with a maximum of 2 figures and 2 tables and a compact current list of not more than 15 references.
Authors should state in a covering letter to the Editor-in-Chief why their paper should receive priority handling.
Reports of new or improved methods should be as brief as is consistent with clarity (up to about 1000 words). They should unequivocally identify the element of novelty claimed and the advantages over existing technology. Performance characteristics, including effects of interfering substances, comparisons with results of accepted methods and reference values based on appropriate population samples should be documented by adequate data. Citing of earlier publications is preferred to repetition of details for reagents, procedures, etc., which are always in print. Nevertheless, the information provided must suffice to allow readers to duplicate the work or to compare the technique with current practice. Instrument and kit evaluations usually will not be accepted unless a new principle is involved.
Acknowledgements
Only persons who have made substantial contributions to the work should be acknowledged. Authors are responsible for obtaining written permission from everyone acknowledged by name because readers may infer their endorsement of the data and conclusions.
The source(s) of support in the form of grants, equipment, drugs, or all of these should be acknowledged here.
References
Type references double-spaced and number them consecutively in the order in which they are first quoted in the text. Identify references in text, tables and legends by arabic numerals [square brackets]. References cited only in tables or in legends to figures should be numbered in accordance with a sequence established by the first identification in the text of the particular table or illustrations. Please note that all authors should be listed when six or less; when seven or more, list only the first three and add et al. The names of journals should be abbreviated according to the list of serial title word abbreviations (ISDS, Paris, l985, ISBN 2-904938-02-8).
Do not include references to personal communications, unpublished data or manuscripts either 'in preparation' or 'submitted for publication'. Reference to a paper as 'in press' implies that it has been accepted for publication. Recheck references in the text against the reference list after your manuscript has been revised and renumber accordingly.
Incomplete references can result in publication delay.
Examples of correct forms of references are as follows:
[1] Lott JA,Curtis LW, Thompson A, Gechlik GA, Rund DA. Reported alcohol consumption and the serum carbohydrate-deficient transferrin test in third-year medical students. Clin Chim Acta 1998; 276:121-128
[2] Strunk W, White EB, The elements of style, third ed. New York: Macmillan, 1979.
[3] Kennedy L. Glycation of haemoglobin and serum proteins. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, editors. International textbook of Diabetes Mellitus. Chichester: John Wiley, 1992: 985-1007.
Tables
Tables should be used sparingly; they should be used only when the data cannot be presented clearly in the text. Each table, and every column should be provided with an explanatory heading, with units of measure clearly indicated. The heading of the table should make its general meaning understandable without reference to the text. Authors are requested to consult recent issues of CCA for the proper table layout. Cite each table in the text in consecutive order.
The Editor-in-Chief, on accepting a manuscript, may recommend that additional tables containing important backup data, too extensive to be published, may be deposited with the National Auxiliary Publications Service or made available by the author(s). In that event, an appropriate statement will be added to the text. Submit such tables for consideration with the manuscript.
Illustrations
Figures should be used to illustrate experimental results clearly. Symbols, lettering and lines should be of sufficient size to ensure legibility after reduction. Figures should be professionally drawn and photographed and at least one set should be presented as glossy, high contrast, black-and-white photographs or laser prints. Titles and detailed explanations belong in the figure legends and not in the illustrations themselves.
Each figure should bear the figure number, the name of the corresponding author and the (shortened) title of the paper on the reverse side. Figures should never be folded and they should never be mounted on heavy card. Continuous or half-tone figures should have their labelling supplied as an overlay, or be supplied in duplicate.
The size of symbols in relation to lettering should be chosen carefully. Magnification should be indicated by a line representing the actual scale of reproduction (0.1  m, 1 m or 10 m).
When essential to the understanding of a paper, figures may be reproduced in colour, at the author's own expense. Authors should take into consideration that colour illustrations reproduced from a slide provide a better-quality, clearer result than those reproduced from a photograph.
Cite each figure in the text in consecutive order. If a figure has been published, acknowledge the original source and submit written permission from the copyright holder to reproduce the material.
For further information on artwork please see our website: http://authors.elsevier.com
Legends for illustrations
As a general rule, an illustration with its legend should be able to be understood by the reader without reference to the general text. Legends must therefore contain sufficient information about methods and experimental design to make them self-explanatory.
Legends should be collated and typed double-spaced, and numbered with arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one clearly in the legend. Explain internal scale and identify method of staining in photomicrographs.
Quantities and units
These should be in conformity with international practice relating to the use of SI units: thus concentrations of solutes of known molecular mass should normally be stated in mol/l or recognized submultiples thereof (nmol/l, etc.). Other solutes should be expressed in g/l, mg/l, etc. Reagent composition may be specified either in molar terms or in mass or volume of each solute per liter of final solution (% or w% should not be used). Enzyme activities should be reported in katals or U/l whenever possible and should be accompanied by a reference to, or a description of, the procedure used for the measurements.
ELECTRONIC MANUSCRIPTS
Authors are required to submit electronic manuscripts. Typesetting from computer files has several advantages, not the least of which is the avoidance of re-keying errors in the article.
The following points should be taken into account when preparing electronic manuscripts.
1. Files produced by most commercial wordprocessing software packages can be used directly by the Publisher. Save your files as usual on a disk specifying what computer was used (IBM-compatible PC, Apple Macintosh etc.). For other systems, please contact the Issue Manager at Elsevier Science Ltd. Please do not save your text as ASCII or similar: this will cause all special formatting codes to be lost.
The output from specific desktop publishing (DTP) software (e.g., Quark Xpress, Pagemaker etc.) include a considerable amount of coding which will interfere with normal file processing. Such DTP output should therefore be avoided.
2. Authors should not use (or allow their word processor to introduce) any hyphenation or word splits and they should not use a 'justified' layout.
3. Authors should ensure that the digit '1' and the letter 'l' (also the digit '0' (zero) and the capital letter 'O') have been used properly. The letter X and the 'times' sign, the apostrophe and the prime, and the hyphen and dash (for minus, etc.) represent further sources of confusion.
4. If the word processor or printer has any special characters, e.g., ? ? ? n, Greek letters and mathematical symbols, they should be used consistently throughout the text.
5. Non-reproducible characters should not be left as blank spaces in the file, but should be replaced by character or codes not used elsewhere, and should be used consistently, e.g., sigma for  . A list of such characters (codes) and a lexicon of what they actually represent should be added as a separate file on the disk.
6. Facilities for 'automatic' numbering of references and footnotes should not be used.
The following points should be taken into account in submitting electronic manuscripts:
1. The file must contain the final corrected version of the article and must match exactly the accompanying hardcopy printout of the final (revised) manuscript.
2. Figures and tables also may be handled electronically, but hardcopy of all figures must be supplied.
3. The disk should be labelled with:
- the name of the author who will receive the proofs
- the manuscript reference number (when known)
- the software and hardware used
- the names of the files.
4. Keep a back-up disk for reference and safety.
ELECTRONIC SUBMISSIONS
As part of the development of an electronic submission system for Clinica Chimica Acta, Dr. A. Wu, Editor-in-Chief for the Americas, Japan and Asia, is willing to accept e-mail submissions if they are in an appropriate format. Submissions may be sent by e-mail to us-cca@attbi.com providing that the manuscript is in MS Word, figures are in MS Word or MS PowerPoint, and tables are in MS Word or MS Excel. This is the only on-line, electronic submission possibility for Clinica Chimica Acta at this time, however this will change in the future.
Editorial Board
|
Editors-in-Chief:
 |
|
D.W. Moss, Department of Metabolic Medicine, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
Fax: (+44) 20 8383 3232
Email:uk_cca@btinternet.com
|
|
A.H. Wu, Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102-5037, USA.
Fax: (+1) 860 217 0361
Email:us-cca@comcast.net
|
Reviews Editor:
|
|
G.S. Makowski, Department of Laboratory Medicine, MC-2235, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-2235, USA.
Fax: (+1) 860 679 2154
Email:Makowski@nso1.uchc.edu
|
Editorial Board:
|
|
N. Amino, Osaka, Japan
|
|
D.J. Anderson, Cleveland, OH, USA
|
|
R. Bais, St Leonards, NSW, Australia
|
|
R. Beetham, Bristol, UK
|
|
A. Boersma, Lille, France
|
|
C. Bohuon, Paris, France
|
|
D. Bullock, Birmingham, UK
|
|
D.W. Chan, Baltimore, MD, USA
|
|
T.K. Christopoulos, Patras, Greece
|
|
W.B. Coleman, Chapel Hill, NC, USA
|
|
A. Dasgupta, Houston, TX, USA
|
|
A. De Leenheer, Gent, Belgium
|
|
E.P. Diamandis, Toronto, ON, Canada
|
|
J.G. Donnelly, New York, NY, USA
|
|
B.T. Doumas, Whitefish Bay, WI, USA
|
|
R. Felder, Charlotttesville, VA, USA
|
|
D.M. Goldberg, Toronto, ON, Canada
|
|
B. Goldberger, Gainesville, FL, USA
|
|
A.M. Gronowski, St.Louis, MO, USA
|
|
C. Hammett-Stabler, Chapel Hill, NC, USA
|
|
P.E. Hickman, Woden, ACT, Australia
|
|
P.J. Howanitz, Brooklyn, NY, USA
|
|
P. Kamoun, Paris, France
|
|
L.A. Kaplan, New York, NY, USA
|
|
G.J. Kost, Davis, CA, USA
|
|
G.M. Kostner, Graz, Austria
|
|
I.D. Laios, Milpitas, CA, USA
|
|
C. Lee, Galveston, TX, USA
|
|
S. Li, Westmead, NSW, Australia
|
|
J.A. Lott, Columbus, OH, USA
|
|
M.M. M¨¹ller, Vienna, Austria
|
|
R.A. Mooney, Rochester, NY, USA
|
|
A.O. Okorodudu, Galveston, TX, USA
|
|
N. Okumura, Matsumoto, Japan
|
|
M. Plebani, Padova, Italy
|
|
C.P. Price, Slough, UK
|
|
K. Pulkki, Helsinki, Finland
|
|
P.M. Rainey, Seattle, WA, USA
|
|
N. Rifai, Boston, MA, USA
|
|
F. Salvatore, Naples, Italy
|
|
N.E. Saris, Helsinki, Finland
|
|
S. Scharp¨¦, Wilrijk, Belgium
|
|
M.K. Schwartz, New York, NY, USA
|
|
J. Shepherd, Glasgow, UK
|
|
L.M. Silverman, Charlottesville, VA, USA
|
|
I.-K. Tan, Singapore
|
|
J.J.H. Thijssen, Utrecht, The Netherlands
|
|
J.G. Toffaletti, Durham, NC, USA
|
|
M. Tozuka, Matsumoto, Japan
|
|
G. Tsongalis, Hartford, CT, USA
|
|
R. Valdes, Louisville, KY, USA
|
|
P.R. Wenham, Edinburgh, UK
|
|
F. Wians, Dallas, TX, USA
|
|
J.S. Woodhead, Cardiff, UK
|
|
K. Yeung, Elkhart, IN, USA
|
|
刊名字顺( Alphabetical List of Journals):
返回页首 